Schrödinger (NASDAQ: SDGR) announced a strategic collaboration and software agreement with Bristol Myers Squibb (NYSE: BMY) to deploy Bunsen, Schrödinger's AI Co-Scientist platform, for agentic drug discovery. The collaboration aims to accelerate drug research by combining AI-driven scientific reasoning with Schrödinger's computational drug discovery technologies. Sector: Biotechnology / Artificial Intelligence Key Highlights 🤝 Schrödinger and Bristol Myers Squibb entered a strategic collaboration 🤖 Deploying Bunsen AI Co-Scientist for agentic drug discovery 🧬 Integrates AI with computational drug research workflows ⚙️ Designed to accelerate target discovery and therapeutic development 🚀 Expands the use of AI across pharmaceutical R&D Why It Matters The partnership highlights the growing adoption of AI in drug discovery, enabling researchers to accelerate scientific decision-making and improve the efficiency of developing next-generation therapies. Read More: https://www.thinksabio.com/reports/isr/SDGR